Update on diabetic cardiomyopathy: Inches forward, miles to go

Current Diabetes Reports

Volumn 12, Issue 3, 2012, Pages 305-313

  Tillquist, Maggie N ^a   Maddox, Thomas M ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Diabetes mellitus; Diabetic cardiomyopathy; Heart failure; Hyperglycemia; Insulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANNABIDIOL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; PIOGLITAZONE; TRIMETAZIDINE;

ANGINA PECTORIS; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECHOCARDIOGRAPHY; EPIGENETICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MICROANGIOPATHY; PATHOGENESIS; PHENOTYPE; PREVALENCE; SEROLOGY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIABETIC NEUROPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; RISK FACTORS;

EID: 84861094607     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0274-7     Document Type: Article

References (53)

1. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595-602.
2. Aneja A, Tang W, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748-57.
3. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol. 2007;99(4):113-32. (Pubitemid 46239953)
4. Battiprolu P, Gillette T, Wang Z, Lavandero S, Hill J. Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech. 2010;7(2):e135-43.
5. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543-67. (Pubitemid 39096070)
6. Sasso FC, Rambaldi PF, Carbonara O, et al. Perspectives of nuclear diagnostic imaging in diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis. 2010;20(3):208-16.
7. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010;16(12):971-9.
8. Van Buren P, LeWinter M. Heart failure: a companion to Braunwald's heart disease. Chapter 26 - heart failure as a consequence of diabetic cardiomyopathy. Elsevier Inc. 2011. pp. 408-418.
9. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes Mellitus, a predictor of morbidity and mortality in the studies of the left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017-20. (Pubitemid 26158096)
10. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:1967-78.
11. National Diabetes Information Clearinghouse. Available at http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#Diagnosed20. Accessed December 2011.
12. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy - fact or fiction? Herz. 2011;36(2):102-15.
13. Singh G, Sharma R, Khullar M. Epigenetics and diabetic cardiomyopathy. Diabetes Res Clin Pract. 2011;94(1):14-21.
14. Voulgari C, Papadoglannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag. 2010;6:883-903.
15. Mytas DZ, Stougiannos PN, Zairis MN, et al. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications. 2009;23(4):273-82.
16. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48(3):173-81.
17. Wenmeng W, Qizhu T. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses. 2011;76(2):181-3.
18. Rollm N, Ingul C, Hansen H, et al. Increased sensitivity to ischemia in an early diabetic cardiomyopathy: the role of calcium handling. Biophys J. 2009;96(3):119a.
19. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progression diagnosis and treatment. Heart Fail Rev. 2011; [Epub ahead of print].
20. Flotats A, Carrio I. Is cardiac autonomic neuropathy the basis of non-ischemic diabetic cardiomyopathy? JACC: Cardiovasc Imag. 2010;3(12):1216-7.
21. Mustonen J, Mantysaari M, Kuikka J. Decreased myocardial 123Imetaiodobenzylguanidine uptake is associated with disturbed LV diastolic filling in diabetes. Am Heart J. 1992;123:804-5.
22. Bisognano JD, Weinberger HD, Bohimeyer TJ, et al. Myocardialdirected overexpression of the human B(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-30. (Pubitemid 30658918)
23. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta Mol Cell Res. 2011;1813(7):1351-9.
24. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22:118-1190.
25. Kajstura J, Fiordaliso F, Androli AM, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-medicated oxidative stress. Diabetes. 2001;50:1414-24. (Pubitemid 32500175)
26. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and preclinical diastolic dysfunction: a population-based study. JACC. 2010;55(4):300-5.
27. Maya L, Villarreal F. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol. 2010;48 (3):524-9.
28. Fang ZY, Schull-Meade R, Downey M, et al. Determinants of subclinical diabetic heart disease. Diabetologia. 2005;48:394-402. (Pubitemid 40543314)
29. Ernande L, Bergerot C, Rietzchel E, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr. 2011;24 (11):1268-75.
30. Ng AC, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104:1398-401.
31. Nakai H, Takeuchi M, Nishikage T, et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. 2009;10:926-32.
32. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive diabetic mellitus. Am J Cardiol. 2004;93:870-5. (Pubitemid 38429599)
33. Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med. 2005;22:1720-5. (Pubitemid 43046474)
34. Kim DH, Kim YJ, Kim HK, et al. Usefulness of mitral annulus velocity for the early detection of left ventricular dysfunction in a rat model of diabetic cardiomyopathy. J Cardiovasc Ultrasound. 2010;18(1):6-11.
35. Thrainsdottir I, Maimberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res. 2004;1:40-3.
36. Rosen R, Rump AF, Rosen P. The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. Diabetologia. 1995;38:509-17.
37. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524-32.
38. Epshteyn V, Morrison K, Krishnaswamy P, et al. Utility of Btype natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 2003;26:2081-7. (Pubitemid 41184256)
39. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-e90.
40. Romano S, Mauro M, Fratini S, et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc Diabetol. 2010;9:89.
41. Mogelvang R, Goetze JP, Pedersen SA, et al. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. J Card Fail. 2009;15:489-95.
42. Betti I, Castelli G, Barchielli A, et al. The role of N-terminal PRObrain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009;15:377-84.
43. Ihm S, et al. Serum carboxy-terminal propeptide of type 1 procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol 2007;e36-8. (Pubitemid 47615193)
44. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-95. (Pubitemid 46294729)
45. Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidencebased strategies. Vasc Health Risk Manag. 2009;5:859-71.
46. Von Bibra H, Hansen A, Dounis V, et al. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Hear Vessel. 1994;9:121-8.
47. Von Bibra H, Siegmund T, Hansen A, et al. Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus. Dtsch Med Wochenschr. 2007;132:729-34. (Pubitemid 46739687)
48. Bibra H, Siegmund T, Ceriello A, et al. Optimized postprandial glucose control is associated with improved cardiac/vascular function - comparison of three insulin regimens in well-controlled type 2 diabetes. Horm Metab Res. 2009;41(2):109-15.
49. Hordern MD, Coombes JS, Cooney LM, et al. Effects of exercise intervention on myocardial function in type 2 diabetes. Heart. 2009;95(16):1343-9.
50. Naka KK, Pappas K, Papathanassiuo K, et al. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue Doppler imaging study. Cardiovasc Diabetol. 2010;23:9-57.
51. Hare JL, Horder MD, Leano R, et al. Application of an exercise intervention on the evolution of diastolic dysfunction in patients with diabetes mellitus: efficacy and effectiveness. Circ Heart Fail. 2011;4(4):441-9.
52. ADVANCE Echocardiography Substudy Investigators, ADVANCE Collaborative Group. Effects of perinopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. J Hypertens. 2011;29 (7):1439-47.
53. Rajesh M, Mukhopadyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56(25):2115-25.